Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Anika Therapeutics (ANIK) reported Q3 2025 results. Revenue was $27.8M with gross margin at 56%, producing a net loss of $2.3M and a loss from continuing operations of $3.2M. Adjusted EBITDA was $0.9M. For the nine months, revenue totaled $82.2M with gross margin at 54% and a net loss of $11.2M.
Channel mix shifted: OEM revenue declined 20% in Q3, driven by lower pricing from J&J MedTech, while Commercial Channel grew 22%. J&J MedTech represented 51% of Q3 revenue. Cash and cash equivalents were $58.0M, and no repurchases occurred in Q3 after completing the first $15.0M tranche of the $40.0M program by June 2025.
Strategically, Anika completed the sales of Arthrosurface and Parcus Medical and sharpened focus on OA Pain Management and Regenerative Solutions. J&J MedTech extended exclusive U.S. rights to market Monovisc through December 2031. For Hyalofast, the U.S. pivotal study did not meet co-primary endpoints, but the final PMA module was submitted on October 31, 2025, supported by improvements on key secondary endpoints.
Anika Therapeutics (ANIK) reported Q3 2025 results. Revenue was $27.8M with gross margin at 56%, producing a net loss of $2.3M and a loss from continuing operations of $3.2M. Adjusted EBITDA was $0.9M. For the nine months, revenue totaled $82.2M with gross margin at 54% and a net loss of $11.2M.
Channel mix shifted: OEM revenue declined 20% in Q3, driven by lower pricing from J&J MedTech, while Commercial Channel grew 22%. J&J MedTech represented 51% of Q3 revenue. Cash and cash equivalents were $58.0M, and no repurchases occurred in Q3 after completing the first $15.0M tranche of the $40.0M program by June 2025.
Strategically, Anika completed the sales of Arthrosurface and Parcus Medical and sharpened focus on OA Pain Management and Regenerative Solutions. J&J MedTech extended exclusive U.S. rights to market Monovisc through December 2031. For Hyalofast, the U.S. pivotal study did not meet co-primary endpoints, but the final PMA module was submitted on October 31, 2025, supported by improvements on key secondary endpoints.
Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025. The company states this information is being furnished, not filed, under the Exchange Act. The earnings press release is attached as Exhibit 99.1.
Anika also announced a regulatory milestone for Hyalofast. The company filed the third and final module of its Premarket Approval application for Hyalofast, a resorbable, hyaluronic acid‑based scaffold used with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee, and reported results from its U.S. pivotal Phase III FastTRACK trial evaluating Hyalofast. This update is provided via a separate press release attached as Exhibit 99.2.
Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025. The company states this information is being furnished, not filed, under the Exchange Act. The earnings press release is attached as Exhibit 99.1.
Anika also announced a regulatory milestone for Hyalofast. The company filed the third and final module of its Premarket Approval application for Hyalofast, a resorbable, hyaluronic acid‑based scaffold used with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee, and reported results from its U.S. pivotal Phase III FastTRACK trial evaluating Hyalofast. This update is provided via a separate press release attached as Exhibit 99.2.
On 30 Jul 2025, Anika Therapeutics (ANIK) filed a Form 8-K (Item 7.01) to furnish a press release (Exhibit 99.1) announcing top-line results from its U.S. pivotal FastTRACK Phase III study of the Hyalofast cartilage-repair scaffold and providing a program update. No financial figures, efficacy data, or regulatory timelines are included in the filing itself; those details reside in the furnished press release, which is not reproduced here. The information is deemed “furnished,” not “filed,” so it is excluded from Exchange Act liability and will not be automatically incorporated into future SEC filings. Apart from the exhibit list, the 8-K contains no additional disclosures under Items 1–6, and there are no financial statements attached.
On 30 Jul 2025, Anika Therapeutics (ANIK) filed a Form 8-K (Item 7.01) to furnish a press release (Exhibit 99.1) announcing top-line results from its U.S. pivotal FastTRACK Phase III study of the Hyalofast cartilage-repair scaffold and providing a program update. No financial figures, efficacy data, or regulatory timelines are included in the filing itself; those details reside in the furnished press release, which is not reproduced here. The information is deemed “furnished,” not “filed,” so it is excluded from Exchange Act liability and will not be automatically incorporated into future SEC filings. Apart from the exhibit list, the 8-K contains no additional disclosures under Items 1–6, and there are no financial statements attached.
On 24 June 2025, Anika Therapeutics (ANIK) filed a Form 4 reporting that director Susan L. N. Vogt was granted 14,164 restricted stock units (RSUs) on 20 June 2025. Transaction code "A" confirms the award was a non-cash grant priced at $0.
Each RSU entitles the holder to one common share and will vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026. Following the grant, Vogt's beneficial ownership increased to 50,213 common shares, a notable rise from her prior level.
No derivative securities, sales, or additional acquisitions are disclosed. The filing represents routine director compensation and is unlikely to materially affect Anika Therapeutics' financial condition or share-count, but it strengthens insider alignment with shareholder interests.
Anika Therapeutics (NASDAQ:ANIK) filed a Form 4 reporting that director Stephen Richard received 14,164 restricted stock units (RSUs) on 06/20/2025 at a cost basis of $0. The RSUs vest in full on the earlier of the 2026 annual shareholder meeting or 06/20/2026. After the grant, Richard’s direct beneficial ownership increased to 47,871 common shares.
The filing reflects a routine board compensation award; no open-market purchases or sales were disclosed.
Director equity grant highlighted in Form 4 filing
On 20 June 2025, Anika Therapeutics (ticker: ANIK) director Glenn R. Larsen received an award of 14,164 restricted stock units (RSUs) at an exercise price of $0. Each RSU represents the right to one share of common stock. The units vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026.
After the grant, Larsen’s direct beneficial ownership rises to 50,258 common shares. No sales, option exercises or other derivative transactions were reported. The filing reflects routine director compensation rather than an open-market purchase, therefore cash was not exchanged and there is no immediate impact on the company’s outstanding share count or cash position.
While the additional ownership marginally strengthens management–shareholder alignment, the transaction is typical for board-level remuneration and is not by itself a material catalyst for the stock.
Anika Therapeutics (ANIK) – Form 4 insider filing: Director William R. Jellison reported the grant of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts to one common share upon vesting, which will occur in full at the earlier of the company’s 2026 annual meeting or 20 June 2026. Following the award, Jellison’s direct ownership rises to 20,403 common shares; he also holds 2,700 shares indirectly through a revocable trust. No shares were sold or disposed of, and the grant was made at $0 cost, reflecting a routine, equity-based director compensation transaction.
Anika Therapeutics, Inc. (ANIK) filed a Form 4 on 24 June 2025 detailing an insider equity award to director John B. Henneman III. On 20 June 2025 Mr. Henneman received 14,164 restricted stock units (RSUs) of common stock at a stated price of $0. Each RSU represents the contingent right to receive one ANIK share.
The RSUs vest in full on the earlier of the company’s 2026 annual shareholder meeting or 20 June 2026, aligning the award’s time horizon with shareholder interests over the next 12 months. Following the grant, Mr. Henneman’s total directly held beneficial ownership rises to 49,871 common shares. No derivative securities were exercised, sold, or otherwise disposed of in this filing, and no cash changed hands; the transaction is classified under code “A” (award) under SEC rules.
This appears to be a routine component of director compensation rather than an open-market purchase, yet it still modestly increases insider exposure to the stock. No other material transactions, earnings data, or financial tables were included in the filing.